MS-377

MS-377 (also known as Seclidemstat) is a nonsteroidal anti-inflammatory drug (NSAID) derivative that acts as a selective monoamine oxidase inhibitor. It is primarily used in the treatment of schizophrenia and Parkinson's disease.

History[edit | edit source]

MS-377 was first synthesized in the late 20th century as part of a series of compounds designed to treat neurological disorders. Its unique mechanism of action and potential therapeutic benefits led to its further development and clinical trials.

Pharmacology[edit | edit source]

MS-377 is a selective inhibitor of monoamine oxidase, a type of enzyme that breaks down neurotransmitters in the brain. By inhibiting this enzyme, MS-377 increases the levels of certain neurotransmitters, such as dopamine, serotonin, and norepinephrine, which can help to alleviate the symptoms of schizophrenia and Parkinson's disease.

Clinical Use[edit | edit source]

MS-377 is primarily used in the treatment of schizophrenia, a mental disorder characterized by abnormal behavior, strange speech, and a decreased ability to understand reality. It is also used in the treatment of Parkinson's disease, a long-term degenerative disorder of the nervous system that mainly affects the motor system.

Side Effects[edit | edit source]

Like all drugs, MS-377 can cause side effects. These can include nausea, vomiting, dizziness, and insomnia. In rare cases, it can cause more serious side effects, such as seizures or hallucinations.